Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2018

Oct 29, 2018

SELL
$12.7 - $15.79 $599,846 - $745,793
-47,232 Closed
0 $0
Q2 2018

Aug 03, 2018

BUY
$10.99 - $44.21 $519,079 - $2.09 Million
47,232 New
47,232 $689,000

Others Institutions Holding PRTA

About PROTHENA CORP PUBLIC LTD CO


  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $714M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Price Capital Management, Inc. Portfolio

Follow Price Capital Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price Capital Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Price Capital Management, Inc. with notifications on news.